CDKN2A/P14arf Polyclonal Antibody, RBITC Conjugated

Größe

£427.00

SKU:: BS-22495R-RBITC
Zusätzliche Namen:: CDKN2A; p16INK4a; INK4; P16INK4; ARF; CCM2; CDK4 Inhibitor; CDK4 inhibitor p16 INK4; CDK4I; CDKN2; CDKN2A; Cell cycle negative regulator beta; CMM2; Cyclin dependent kinase 4 inhibitor A; Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4); Cyclin Dependent Kinase Inhibitor 2A; Cyclin dependent kinase inhibitor 2A isoform 4; Cyclin dependent kinase inhibitor 2A isoforms 1/2/3; Cyclin dependent kinase inhibitor p16; INK4A; MLM; MTS1; Multiple tumor suppressor 1; Multiple Tumor Supressor 1; p14; p14(ARF); p14ARF; p16; p16 INK4; p16INK4; p16INK4a; p19; p19(ARF); p19Arf; TP16.
Anwendung:: WB
Konzentration:: 1ug/ul
Quelle:: KLH conjugated synthetic peptide derived from human CDKN2A/P14arf
Aufreinigung:: Purified by Protein A.
Forschungsgebiet:: Cancer
Lagerbedingungen:: Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Hersteller:: Bioss Inc
Host:: Rabbit
Reaktivitäten:: Human
Buffer:: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Formulierung:: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Uniprot:: P42771
Gendetails:: 1029